Disease Landscape and Forecast Insights

In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S…

AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through…

Adult OM/PJI due to MRSA are among the most hard-to-treat MRSA infections due to the difficulties for the body’s natural infection-fighting cells and antibiotics to reach the infected tissues in…

As the prevalence of chronic pain associated with numerous indications (e.g., osteoarthritis, cancer) and of idiopathic origin (e.g., chronic back pain) continues to increase in the United States…

Nearly 35 years after the Orphan Drug Act of 1983 (ODA) became law in the United States, private investment in the development of drugs for orphan diseases continues unabated. Although the growing…

The treatment of breast cancer has a rich and diverse product pipeline and continues to be one of the most lucrative and active areas of research in oncology. However, the barriers to entry are…

In the context of growing healthcare costs, vaccines stand out as highly cost-effective products for improving public health. Furthermore, compared with pharmaceuticals, vaccines tend to carry a…

ARDS is an acute, severe lung injury that causes edema of the lung alveoli, leading to breathing abnormalities and insufficient oxygen levels in the circulating blood, which may be life-threatening…

Market Outlook: Immune checkpoint inhibitors are revolutionizing the treatment algorithm for the unresectable locally advanced or metastatic bladder cancer. With the 2016/7 FDA approvals of five…

Market Outlook: Angiogenesis inhibitors continue to be the mainstay of first-line and second-line advanced or metastatic renal cell carcinoma. While PD-1 inhibitor, Opdivo entry in the second-…

Venous thromboembolism ( VTE ), comprising deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ), represents a significant public health and financial burden. The launch of non-vitamin K…

MARKET OUTLOOK Conventional agents (e.g., immunosuppressants, 5-ASAs) have long been used to treat pediatric Crohn’s disease (CD). Among the TNF-α inhibitors, Janssen/Merck’s Remicade and…